Specialty Pharmacy

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.

The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain.

Fabry disease is a rare lysosomal disorder that causes excessive deposition of lipids in tissues.

The treatment is a type IA prodrug of dexamethasone that targets CD206+ macrophages.

Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.

The study also found that HSSPs minimize health costs and provide additional revenue for health systems.

A vast majority of patients achieved a positive clinical response with the combination, with improvements in their ocular condition.

Investigators presented additional data from a clinical trial at the American College of Rheumatology Convergence, demonstrating similar safety for postmenopausal women with osteoporosis.

The biosimilar is approved for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

Rick C. McCoy, RPh, and Marge McCoy, RPh, combine decades of experience working side by side with a dedication to serving their island community.

Augmentation is a condition in which RLS symptoms intensify or change in response to long-term dopamine agonist treatment.

Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.

This marks the first and only therapy to receive this designation for Sjögren disease, which currently has no approved treatment.

An advanced pharmacy practice experience program between a historically Black university and predominantly White institution impacted student perspectives on cultural competency.

Ocrelizumab (Ocrevus; Genentech) is used for the management and treatment of multiple sclerosis.

CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.

The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.

New technology and innovation may help turn the corner on antibiotic resistance.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

The study investigated faricimab-svoa (Vabysmo) as treatment of diabetic macular edema for patients in racial and ethnic groups that are often underrepresented in trials.

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

Oral semaglutide had a safe and well-tolerated profile for individuals with type 2 diabetes, which is in line with those previously reported for the drug in other trials.

Pharmacists play a key role when it comes to medication substitution, especially for interchangeable biosimilars where allowed by state law.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

The call follows the FDA’s sudden removal of tirzepatide from the drug shortage list, preventing compounding pharmacies from providing the drug.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

Despite self-reported improvements in cognitive function, neuropsychological tests showed little differences between 2 patient groups.

The agency does not intend to take action against the plaintiffs for the violation of the Federal Food, Drug, and Cosmetic Act, including the compounding of tirzepatide.

The FDA previously accepted the biologic license application for CT-P13 as a subcutaneous formulation.

In April 2024, the FDA approved ustekinumab-aekn as a subcutaneous injection for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.